Inotek Pharmaceuticals Corp. (ITEK)
The price of ITEK stock skyrocketed more than 50% in early trading Thursday as the company announced that the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eye’s natural pressure control mechanism.
Glaucoma is a disease that damages the eye’s optic nerve and can result in vision loss and blindness. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in the eye, damaging the optic nerve.
Based on feedback from a recent End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA), ITEK is in final preparation stages to commence its first Phase 3 trial to support a New Drug Application (NDA) for trabodenoson.
ITEK said that its overall program will consist of three clinical trials encompassing a total subject exposure of 1300 patients and a benefit of the Phase 3 superiority design is that the company can investigate more than one dose of trabodenoson, allowing ITEK to further optimize the drug’s clinical and safety profile
According to ITEK, its previous Phase 2 studies have demonstrated that trabodenoson’s efficacy improves over time, and with increases in dose
ITEK is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases.
More about Inotek Pharmaceuticals Corp. (ITEK) at www.inotekpharma.com
Cara Therapeutics Inc. (CARA)
Shares of CARA soared to touch a new 52-week high on Thursday’s trading session after the company reported statistically significant topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus, a chronic systemic itch condition in patients with renal failure, often receiving hemodialysis.
According to CARA, I.V. CR845 was shown to be safe and well tolerated during the study with no CR845-related serious adverse events reported and the data demonstrate a robust effect of reducing both daytime and nocturnal itching by an objective scoring system as well as anecdotal quality of life histories
There are currently no approved products in the United States for uremic pruritus.
CARA is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.
More about Cara Therapeutics Inc. (CARA) at www.CaraTherapeutics.com.
Crown Equity Holdings Inc. (CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its growing network of community targeted sites, expected to be a one-stop shop for the various needs of consumers.
CRWE Network’s business model is based on selling advertising to businesses targeting both locally and nationally
CRWE‘s Curbiz ( www.curbiz.com ), in development stage, is an online business directory connecting people with local, state, country and global businesses. Curbiz will provide local advertising services, including free and paid business listing services to businesses of various sizes, as well as enable businesses to deliver targeted search advertising to large local audiences through its Website and partnership with the CRWE Network.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer